1. Home
  2. DAWN vs TPC Comparison

DAWN vs TPC Comparison

Compare DAWN & TPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • TPC
  • Stock Information
  • Founded
  • DAWN 2018
  • TPC 1894
  • Country
  • DAWN United States
  • TPC United States
  • Employees
  • DAWN N/A
  • TPC N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • TPC General Bldg Contractors - Nonresidential Bldgs
  • Sector
  • DAWN Health Care
  • TPC Consumer Discretionary
  • Exchange
  • DAWN Nasdaq
  • TPC Nasdaq
  • Market Cap
  • DAWN 1.2B
  • TPC 1.4B
  • IPO Year
  • DAWN 2021
  • TPC N/A
  • Fundamental
  • Price
  • DAWN $12.43
  • TPC $22.06
  • Analyst Decision
  • DAWN Strong Buy
  • TPC Strong Buy
  • Analyst Count
  • DAWN 7
  • TPC 2
  • Target Price
  • DAWN $36.17
  • TPC $39.50
  • AVG Volume (30 Days)
  • DAWN 782.5K
  • TPC 596.5K
  • Earning Date
  • DAWN 02-25-2025
  • TPC 02-27-2025
  • Dividend Yield
  • DAWN N/A
  • TPC N/A
  • EPS Growth
  • DAWN N/A
  • TPC N/A
  • EPS
  • DAWN N/A
  • TPC N/A
  • Revenue
  • DAWN $101,953,000.00
  • TPC $4,280,743,999.00
  • Revenue This Year
  • DAWN N/A
  • TPC $13.06
  • Revenue Next Year
  • DAWN $35.37
  • TPC $14.06
  • P/E Ratio
  • DAWN N/A
  • TPC N/A
  • Revenue Growth
  • DAWN N/A
  • TPC 13.69
  • 52 Week Low
  • DAWN $11.13
  • TPC $8.79
  • 52 Week High
  • DAWN $18.07
  • TPC $34.55
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 52.15
  • TPC 35.29
  • Support Level
  • DAWN $11.65
  • TPC $22.51
  • Resistance Level
  • DAWN $12.54
  • TPC $24.72
  • Average True Range (ATR)
  • DAWN 0.47
  • TPC 1.02
  • MACD
  • DAWN 0.02
  • TPC -0.11
  • Stochastic Oscillator
  • DAWN 80.53
  • TPC 2.21

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

About TPC Tutor Perini Corporation

Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. It plans and schedules the manpower, equipment, materials, and subcontractors required for a project. Tutor Perini has three operating segments: civil, building, and specialty contractors and generates majority revenue from civil segment. The company offers self-performed construction services, including site work, concrete forming, steel erection, electrical, mechanical, and heating, ventilation, and air conditioning, or HVAC. The majority of its total revenue is derived from the United States.

Share on Social Networks: